No new Lykos/MDMA resubmission acceptance is announced by FDA before November 2026 despite nominee hype.

Lykos Therapeutics wants to resubmit its application to get MDMA-assisted therapy approved as a treatment in the US. The prediction is that the FDA (the US Food and Drug Administration, the country's drug regulator) won't formally accept that resubmission before November 2026. This matters because millions of people with PTSD (post-traumatic stress disorder) are waiting for a new treatment option.

A leadership nominee cannot compress the review of an NDA lacking new confirmatory data. The absence of MDMA data signals today confirms nothing is imminent.